Royalty Pharma plc Amortization of Debt Issuance Costs and Discounts
Royalty Pharma plc (RPRX) reported Amortization of Debt Issuance Costs and Discounts of $11.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-05
- Royalty Pharma plc amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $5.81M, a 9.46% increase year-over-year.
- Royalty Pharma plc amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $5.71M, a 8.16% increase year-over-year.
- Royalty Pharma plc amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $5.72M, a 7.73% increase year-over-year.
- Royalty Pharma plc amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $6.14M, a 14.77% increase year-over-year.
- Royalty Pharma plc amortization of debt issuance costs and discounts for fiscal 2025 was $22.44M, a 14.71% increase from fiscal 2024.
- Royalty Pharma plc amortization of debt issuance costs and discounts for fiscal 2024 was $19.56M, a 4.57% decline from fiscal 2023.
- Royalty Pharma plc amortization of debt issuance costs and discounts for fiscal 2023 was $20.50M, a 4.01% decline from fiscal 2022.
- Royalty Pharma plc amortization of debt issuance costs and discounts for fiscal 2022 was $21.36M, a 5.92% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $11.52M 10-Q · filed 2026-08-05 | $17.23M derived: sum of 3 quarters · filed 2026-08-05 | $23.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $5.71M 10-Q · filed 2026-05-06 | $11.43M derived: sum of 2 quarters · filed 2026-05-06 | $17.57M derived: sum of 3 quarters · filed 2026-05-06 | $22.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $5.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $11.85M derived: sum of 2 quarters · filed 2026-02-11 | $17.16M derived: sum of 3 quarters · filed 2026-08-05 | $22.44M 10-K · filed 2026-02-11 |
| 2025-09-30 | $6.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $11.44M derived: sum of 2 quarters · filed 2026-08-05 | $16.72M 10-Q · filed 2025-11-05 | $22.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $10.59M 10-Q · filed 2026-08-05 | $15.89M derived: sum of 3 quarters · filed 2026-08-05 | $21.24M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.28M 10-Q · filed 2026-05-06 | $10.59M derived: sum of 2 quarters · filed 2026-05-06 | $15.94M derived: sum of 3 quarters · filed 2026-05-06 | $20.49M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $10.65M derived: sum of 2 quarters · filed 2026-02-11 | $15.21M derived: sum of 3 quarters · filed 2026-02-11 | $19.56M 10-K · filed 2026-02-11 |
| 2024-09-30 | $5.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $9.91M derived: sum of 2 quarters · filed 2025-11-05 | $14.26M 10-Q · filed 2025-11-05 | $19.10M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $4.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $8.91M 10-Q · filed 2025-08-06 | $13.75M derived: sum of 3 quarters · filed 2026-02-11 | $18.76M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $4.35M 10-Q · filed 2025-05-08 | $9.19M derived: sum of 2 quarters · filed 2026-02-11 | $14.20M derived: sum of 3 quarters · filed 2026-02-11 | $19.52M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $9.85M derived: sum of 2 quarters · filed 2026-02-11 | $15.18M derived: sum of 3 quarters · filed 2026-02-11 | $20.50M 10-K · filed 2026-02-11 |
| 2023-09-30 | $5.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $10.33M derived: sum of 2 quarters · filed 2024-11-06 | $15.66M 10-Q · filed 2024-11-06 | $20.99M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $10.65M 10-Q · filed 2024-08-08 | $15.98M derived: sum of 3 quarters · filed 2025-02-12 | $21.32M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $5.32M 10-Q · filed 2024-05-09 | $10.65M derived: sum of 2 quarters · filed 2025-02-12 | $16.00M derived: sum of 3 quarters · filed 2025-02-12 | $21.34M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $10.67M derived: sum of 2 quarters · filed 2025-02-12 | $16.01M derived: sum of 3 quarters · filed 2025-02-12 | $21.36M 10-K · filed 2025-02-12 |
| 2022-09-30 | $5.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $10.68M derived: sum of 2 quarters · filed 2023-11-08 | $16.03M 10-Q · filed 2023-11-08 | $21.37M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $5.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $10.68M 10-Q · filed 2023-08-08 | $16.02M derived: sum of 3 quarters · filed 2024-02-15 | $21.26M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $5.34M 10-Q · filed 2023-05-09 | $10.68M derived: sum of 2 quarters · filed 2024-02-15 | $15.92M derived: sum of 3 quarters · filed 2024-02-15 | $20.71M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $10.58M derived: sum of 2 quarters · filed 2024-02-15 | $15.37M derived: sum of 3 quarters · filed 2024-02-15 | $20.16M 10-K · filed 2024-02-15 |
| 2021-09-30 | $5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $10.03M derived: sum of 2 quarters · filed 2022-11-08 | $14.82M 10-Q · filed 2022-11-08 | $19.67M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $4.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $9.58M 10-Q · filed 2022-08-04 | $14.43M derived: sum of 3 quarters · filed 2023-02-15 | $16.96M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $4.79M 10-Q · filed 2022-05-05 | $9.64M derived: sum of 2 quarters · filed 2023-02-15 | $12.16M derived: sum of 3 quarters · filed 2023-02-15 | $14.03M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $4.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $7.38M derived: sum of 2 quarters · filed 2023-02-15 | $9.24M derived: sum of 3 quarters · filed 2023-02-15 | $11.71M 10-K · filed 2023-02-15 |
| 2020-09-30 | $2.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $4.39M derived: sum of 2 quarters · filed 2021-11-10 | $6.87M 10-Q · filed 2021-11-10 | $10.53M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $4.34M 10-Q · filed 2021-08-11 | $8.00M derived: sum of 3 quarters · filed 2022-02-15 | $11.17M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $2.48M 10-Q · filed 2021-05-11 | $6.14M derived: sum of 2 quarters · filed 2022-02-15 | $9.30M derived: sum of 3 quarters · filed 2022-02-15 | |
| 2019-12-31 | $3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $6.83M derived: sum of 2 quarters · filed 2022-02-15 | $12.79M 10-K · filed 2022-02-15 | |
| 2019-09-30 | $3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $9.13M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $5.96M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $13.13M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |